ArticleHypertension (Dallas, Tex. : 1979)2010
Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice.
Article in Hypertension (Dallas, Tex. : 1979), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 92 citations in OpenAlex.
- Trial
- Defective efferocytosis links autonomic dysfunction and atrial fibrillation: multi-omics integration andFrontiers in immunology · 2026Article
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment.Journal of the American College of Cardiology · 2025Review
- Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the ATFrontiers in pharmacology · 2024Article
- Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats.Saudi journal of biological sciences · 2023Article
- Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?Diabetology & metabolic syndrome · 2022Review
- Mitochondrial Effects of Common Cardiovascular Medications: The Good, the Bad and the Mixed.International journal of molecular sciences · 2022Review
- Benefits of Valsartan and Amlodipine in Lipolysis through PU.1 Inhibition in Fructose-Induced Adiposity.Nutrients · 2022Article
- Kidney Damage Caused by Obesity and Its Feasible Treatment Drugs.International journal of molecular sciences · 2022Review
- Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice.Frontiers in endocrinology · 2022Article
- Role of the central renin‑angiotensin system in hypertension (Review).International journal of molecular medicine · 2021Review
- Inhibition of the Renin-Angiotensin System Reduces Gene Expression of Inflammatory Mediators in Adipose Tissue Independent of Energy Balance.Frontiers in endocrinology · 2021Article
- Angiotensin II Increases Endoplasmic Reticulum Stress in Adipose Tissue and Adipocytes.Scientific reports · 2019Article
- MOF Capacitates Cyclodextrin to Mega-Load Mode for High-Efficient Delivery of Valsartan.Pharmaceutical research · 2019Article
- Pancreatic AT1aR Deficiency Decreases Insulin Secretion in Obese C57BL/6 Mice.American journal of hypertension · 2019Article
- Low molecular weight galactomannans-based standardized fenugreek seed extract ameliorates high-fat diet-induced obesity in miceRSC advances · 2018Article
- Identification of beagle food taking patterns and protocol for food effects evaluation on bioavailability.Scientific reports · 2018Article
- Chronic AT1 blockade improves glucose homeostasis in obese OLETF rats.The Journal of endocrinology · 2018Article
- Immunologic and endocrine functions of adipose tissue: implications for kidney disease.Nature reviews. Nephrology · 2018Review
- Key Role of STAT4 Deficiency in the Hematopoietic Compartment in Insulin Resistance and Adipose Tissue Inflammation.Mediators of inflammation · 2017Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Obesity, hypertension, cardiovascular disease, and inflammation are closely associated with the rising incidence of diabetes mellitus. One pharmacological target that may have significant potential to lower the risk of obesity-related diseases is the angiotensin type 1 receptor (AT1R). We examined the hypothesis that the AT1R blocker valsartan reduces the metabolic consequences and inflammatory effects of a high-fat (Western) diet in mice. C57BL/6J mice were treated by oral gavage with 10 mg/kg per day of valsartan or vehicle and placed on either a standard chow or Western diet for 12 weeks. Western diet-fed mice given valsartan had improved glucose tolerance, reduced fasting blood glucose levels, and reduced serum insulin levels compared with mice fed a Western diet alone. Valsartan treatment also blocked Western diet-induced increases in serum levels of the proinflammatory cytokines interferon-gamma and monocyte chemotactic protein 1. In the pancreatic islets, valsartan enhanced mitochondrial function and prevented Western diet-induced decreases in glucose-stimulated insulin secretion. In adipose tissue, valsartan reduced Western diet-induced macrophage infiltration and expression of macrophage-derived monocyte chemotactic protein 1. In isolated adipocytes, valsartan treatment blocked or attenuated Western diet-induced changes in expression of several key inflammatory signals: interleukin 12p40, interleukin 12p35, tumor necrosis factor-alpha, interferon-gamma, adiponectin, platelet 12-lipoxygenase, collagen 6, inducible NO synthase, and AT1R. Our findings indicate that AT1R blockade with valsartan attenuated several deleterious effects of the Western diet at the systemic and local levels in islets and adipose tissue. This study suggests that AT1R blockers provide additional therapeutic benefits in the metabolic syndrome and other obesity-related disorders beyond lowering blood pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.